Parnassus Investments LLC Grows Stake in Agilent Technologies, Inc. $A

Key Points

• Parnassus Investments LLC increased its stake in Agilent Technologies by 38.3%, acquiring an additional 437,242 shares to reach a total of 1,577,999 shares, which is valued at approximately $184.6 million.
• Agilent reported a quarterly earnings of $1.37 per share, meeting analyst expectations, with a revenue of $1.74 billion, reflecting a 10.1% year-over-year growth.
• Investment analysts have a moderate buy consensus on Agilent Technologies, with an average price target of $139.25, following several revised price objectives from various financial institutions.

Parnassus Investments LLC increased its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 38.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,577,999 shares of the medical research company's stock after purchasing an additional 437,242 shares during the quarter. Parnassus Investments LLC owned 0.55% of Agilent Technologies worth $184,594,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in A. GAMMA Investing LLC boosted its holdings in Agilent Technologies by 15,648.1% during the 1st quarter. GAMMA Investing LLC now owns 627,247 shares of the medical research company's stock valued at $73,375,000 after acquiring an additional 623,264 shares during the period. Two Sigma Investments LP lifted its position in Agilent Technologies by 345.9% in the fourth quarter. Two Sigma Investments LP now owns 769,897 shares of the medical research company's stock valued at $103,428,000 after purchasing an additional 597,249 shares during the last quarter. Iron Triangle Partners LP purchased a new stake in shares of Agilent Technologies during the fourth quarter valued at approximately $80,110,000. Mackenzie Financial Corp grew its holdings in shares of Agilent Technologies by 141.5% in the first quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company's stock worth $109,481,000 after purchasing an additional 548,344 shares during the last quarter. Finally, Two Sigma Advisers LP increased its stake in shares of Agilent Technologies by 380.5% in the fourth quarter. Two Sigma Advisers LP now owns 504,000 shares of the medical research company's stock worth $67,707,000 after buying an additional 399,100 shares during the period.

Analyst Ratings Changes

A has been the subject of several analyst reports. Wall Street Zen raised shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, June 28th. Robert W. Baird raised their target price on Agilent Technologies from $141.00 to $142.00 and gave the stock an "outperform" rating in a research note on Thursday, August 28th. TD Cowen boosted their price target on Agilent Technologies to $150.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Evercore ISI dropped their price objective on Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating for the company in a report on Thursday, August 28th. Finally, UBS Group cut their price objective on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a research report on Thursday, May 29th. Six analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $139.25.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the company's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the transaction, the chief executive officer owned 37,448 shares in the company, valued at approximately $4,397,893.12. This represents a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Agilent Technologies Stock Down 0.4%

Agilent Technologies stock traded down $0.45 during trading hours on Tuesday, hitting $125.21. The stock had a trading volume of 2,124,061 shares, compared to its average volume of 1,950,426. The stock's 50-day moving average price is $118.57 and its 200-day moving average price is $116.30. The stock has a market capitalization of $35.57 billion, a P/E ratio of 29.39, a price-to-earnings-growth ratio of 3.91 and a beta of 1.24. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $153.84. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, meeting the consensus estimate of $1.37. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The firm's quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities research analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.